{
    "name": "remdesivir",
    "comment": "Rx",
    "other_names": [
        "Veklury"
    ],
    "classes": [
        "Antivirals",
        "SARS-CoV-2"
    ],
    "source": "https://reference.medscape.com/drug/veklury-remdesivir-4000090",
    "pregnancy": {
        "common": [
            "There is a pregnancy exposure registry that monitors pregnancy outcomes in individuals exposed to the drug during pregnancy; pregnant and recently pregnant individuals can go to ",
            "Available data from published case reports and compassionate use of remdesivir in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes",
            "Data are not available regarding the presence of remdesivir in human milk, effects on breastfed infants, or effects on milk production"
        ],
        "specific": [
            {
                "type": "Animal studies",
                "description": [
                    "In nonclinical reproductive toxicity studies, remdesivir demonstrated no adverse effect on embryofetal development when administered to pregnant animals at systemic exposures of the predominant circulating metabolite of remdesivir (GS-441524) that were 4 times (rats and rabbits) the exposure in humans at the recommended human dose"
                ]
            },
            {
                "type": "Clinical considerations",
                "description": [
                    "There are maternal and fetal risks associated with untreated COVID-19 in pregnancy; COVID-19 in pregnancy is associated with adverse maternal and fetal outcomes, including preeclampsia, eclampsia, preterm birth, premature rupture of membranes, venous thromboembolic disease, and fetal death"
                ]
            },
            {
                "type": "Animal studies",
                "description": [
                    "In nonclinical reproductive toxicity studies, remdesivir demonstrated no adverse effect on embryofetal development when administered to pregnant animals at systemic exposures of the predominant circulating metabolite of remdesivir (GS-441524) that were 4 times (rats and rabbits) the exposure in humans at the recommended human dose"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Data are not available regarding the presence of remdesivir in human milk, effects on breastfed infants, or effects on milk production"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to drug or any ingredient"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Hypersensitivity, including infusion-related reactions"
            ],
            "specific": [
                {
                    "type": "Hepatic transaminases",
                    "description": [
                        "Hypersensitivity, including infusion-related reactions observed during and following administration; most occur within 1 hr of administration ",
                        "Signs and symptoms may include hypotension, hypertension, tachycardia, bradycardia, hypoxia, fever, dyspnea, wheezing, angioedema, rash, nausea, diaphoresis, and shivering",
                        "Consider slowing infusion rate (up to 120 minutes) to potentially prevent these signs and symptoms; observe patient for 1 hr after completing administration ",
                        "If clinically significant reaction occurs, discontinue immediately and implement appropriate treatment"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Increased hepatic transaminases reported in healthy volunteers and patients with COVID-19",
                        "Because transaminase elevations are reported as a clinical feature of COVID-19, and the incidence in clinical trials was similar in patients receiving placebo versus remdesivir, it is challenging to discern the contribution of remdesivir to transaminase elevations in patients with COVID-19",
                        "ALT levels increase to >10x ULN: Consider discontinuing remdesivir",
                        "ALT elevation accompanied by signs or symptoms of liver inflammation: Discontinue remdesivir"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "chloroquine",
            "description": {
                "common": "chloroquine decreases effects of remdesivir by unspecified interaction mechanism. Avoid or Use Alternate Drug. Coadministration not recommended owing to antagonistic effect on remdesivir?s intracellular metabolic activation and antiviral activity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hydroxychloroquine sulfate",
            "description": {
                "common": "hydroxychloroquine sulfate decreases effects of remdesivir by unspecified interaction mechanism. Avoid or Use Alternate Drug. Coadministration not recommended owing to antagonistic effect on remdesivir?s intracellular metabolic activation and antiviral activity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab decreases effects of remdesivir by immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "remdesivir increases effects of warfarin by unspecified interaction mechanism. Use Caution/Monitor."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "eGFR decreased",
            "percent": "18"
        },
        {
            "name": "Decreased CrCl",
            "percent": "10-18"
        },
        {
            "name": "calculated by Cockcroft",
            "percent": "5-15"
        },
        {
            "name": "Gault",
            "percent": "6-15"
        },
        {
            "name": "Creatinine increased",
            "percent": "11-12"
        },
        {
            "name": "Hemoglobin decreased",
            "percent": "11"
        },
        {
            "name": "Glucose increased",
            "percent": "1-10"
        },
        {
            "name": "Lymphocytes decreased",
            "percent": "9"
        },
        {
            "name": "Prothrombin time increased",
            "percent": "3-8"
        },
        {
            "name": "ALT increased",
            "percent": "6-7"
        },
        {
            "name": "AST increased",
            "percent": "3-5"
        },
        {
            "name": "Nausea",
            "percent": "2"
        },
        {
            "name": "Bilirubin increased",
            "percent": "2"
        },
        {
            "name": "Hypersensitivity reactions",
            "percent": "2"
        },
        {
            "name": "Generalized seizure",
            "percent": "2"
        },
        {
            "name": "Rash",
            "percent": null
        }
    ]
}